Interview with Doru Torge, General Manager, Ferring Pharmaceuticals SA…
Ferring is a company with a tremendous history dating back to the 1950s in Sweden. Now present in over 50 countries, the Group has managed to maintain a double digit…
Address: Coriolan Brediceanu Str., no 10 City Business Center B Building, 1st Floor, Timisoara, Romania
Tel: +40 35 611 32 70
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis.
The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions.
The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.
Ferring has its own production facilities in several European countries, in South America, Israel and China. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring’s marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 50 countries and employ more than 4000 people throughout the world, while treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.
Ferring’s R&D projects complement Ferring’s product portfolio and will add a new generation of products to some of the company’s most successful specialty brands. R&D facilities are located in Denmark, USA, Israel, India and China.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.
For fifty years, we have been at the forefront of innovation in the field of naturally occurring human peptides. We have developed treatments in areas that span the human life cycle, including: reproductive health, endocrinology, gastroenterology and urology:
Ferring’s infertility treatments give infertile couples the chance to have babies
In obstetrics, Ferring helps premature children to be born healthy and without handicaps
With treatments in endocrinology, Ferring gives children the chance to overcome growth deficiencies
Ferring’s inflammatory bowel disease (IBD) treatments enable young adults with IBD to live a normal life
In urology, Ferring’s treatment for nocturia and bedwetting helps adults and children to an undisturbed night’s sleep
Ferring’s testosterone replacement treatment improves the key symptoms of low testosterone, reduces fat and improves muscle strength and mood
Ferring’s hormonal therapy for prostate cancer offers a new treatment option to men with an advanced hormone-dependent cancer
Ferring’s strength is our extensive knowledge of peptides and the role they play in the human body.
Ferring is a company with a tremendous history dating back to the 1950s in Sweden. Now present in over 50 countries, the Group has managed to maintain a double digit…
Sorin Petcu of IQVIA Romania explains how financing, a lack of medical professionals, and an array of unmet needs are the major trends currently shaping Romanian healthcare. Petcu highlights IQVIA’s…
Gabriel Cernica, general manager of Cegedim Customer Information and Cegedim Rx Romania, analyses the main trends shaping the pharmaceutical and healthcare environment in Romania and their effect on Cegedim’s business.…
Amalia Mihai, market access manager of Ipsen Romania explains that over the course of 26 years Ipsen has been increasingly helping Romanian patients in the field of oncology, neurodegenerative disorders,…
Daniel Bran, GM of Accord Romania reveals that finding the right talent has been one of the most challenging and rewarding milestones in building the affiliate from the ground up.…
Cătălin Vicol introduces Biofarm, a leading Romanian pharma producer on the verge of significant international expansion. Vicol shares his insights on the potential of the Romanian consumer healthcare (CHC) market,…
Jorge Levinson, head of Bayer Pharmaceuticals Romania and Moldova, reveals his first impressions of Romania and the untapped potential it offers to the company. He shares his insights on how…
Dana Constantinescu of GSK Romania reveals the importance of the affiliate to the regional group and how vaccines and HIV are driving its growth. She outlines how the affiliate’s portfolio…
Cătălin Radu of Bristol Myers Squibb (BMS) Romania explains how the Celgene acquisition is allowing the company to provide their expertise on a larger scale. He reveals how BMS has…
Cecilia Radu of Novo Nordisk Romania shares her tumultuous four years that have seen declining market share and have culminated in launching the company’s first new product onto the market…
Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the…
Jorge Ruiz Benecke of AbbVie Romania outlines how the affiliate attained its leading position in the Romanian pharma market, the importance of agility in the decision-making process, and how he…
Fotis Kalantzis, general manager for the Romanian affiliate of OTC medicine and food supplement specialist Perrigo reveals how the switch to a consumer-centric model was inducive to winning an IQVIA…
See our Cookie Privacy Policy Here